pharmaceutical investing Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
pharmaceutical investing Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®
pharmaceutical investing Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting
pharmaceutical investing Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm Sublingual Film
pharmaceutical investing InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
pharmaceutical investing Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress
pharmaceutical investing Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid Injectables with JUVÉDERM® at AMWC Monaco
pharmaceutical investing Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
pharmaceutical investing Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts
Syntholene Energy Corp. Announces Engagement of DS Market Solutions Inc. for Liquidity Services and Emerging Markets Consulting for Communications and Marketing Services
Skyharbour Announces Drilling Underway and Renewed Permit at the High-Grade Moore Lake Uranium Project, Saskatchewan
